# In vivo imaging of metabolic heterogeneity across three endpoints relevant to aggressive breast cancer

**Authors:** Victoria W D’Agostino, Michelle Kwan, Adelle Yong, Kira Grossman, Enakshi D Sunassee, Megan C Madonna, Matthew Hirschey, Gregory M Palmer, Nirmala Ramanujam

PMC · DOI: 10.1093/pnasnexus/pgag027 · PNAS Nexus · 2026-02-10

## TL;DR

This study uses a new imaging technique to show how metabolic diversity exists within aggressive breast cancer tumors and normal tissues.

## Contribution

A novel in vivo microscope enables simultaneous imaging of multiple metabolic pathways in breast cancer.

## Key findings

- Tumors showed heterogeneous nutrient preferences, including regions dominated by fatty acid or glucose uptake.
- Normal mammary tissues exhibited uniform oxidative metabolism and high glucose and fatty acid uptake.
- The imaging technique captures spatial metabolic distributions across a 5 mm × 5 mm tumor landscape.

## Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis and a high likelihood of recurrence. Residual disease after therapy is a key predictor of recurrence, often driven by intratumoral metabolic heterogeneity. Accumulating evidence indicates that tumors are able to shift between glycolysis and oxidative metabolism and alter nutrient preferences to sustain growth and resist therapy. We have developed a in vivo microscope that enables near-simultaneous measurements of fluorescent metabolic surrogates of glucose, fatty acids, and oxidative phosphorylation through a combination of spectral separation and sequential delivery schemes. Widefield imaging with uniform illumination across the entire tumor landscape (5 mm × 5 mm) informs on the spatial distribution of these metabolic probes. We used this technology to investigate metabolic heterogeneity of a murine model of TNBC (4T1 tumor line) and normal mammary tissues that have distinctly different metabolic pathways. Mammary tissues relied primarily on oxidative metabolism and showed high levels of glucose and fatty acid uptake across the entire imaging area reflecting a single metabolic phenotype. Though tumors were predominantly glycolytic, they displayed a heterogeneous distribution of nutrient preferences with regions dominated by either fatty acid uptake, glucose uptake, or both. Taken together, this work highlights the importance of not only capturing multiple metabolic endpoints but also investigating their spatial relationships to understand heterogeneity in key substrates and metabolic pathways for energy production in vivo.

## Linked entities

- **Chemicals:** glucose (PubChem CID 5793), fatty acids (PubChem CID 264)
- **Diseases:** breast cancer (MONDO:0004989), triple-negative breast cancer (MONDO:0005494)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Slc27a3 (solute carrier family 27 (fatty acid transporter), member 3) [NCBI Gene 26568] {aka Acsvl3, FATP-3, FATP3, Vlcs-3}, HK1 (hexokinase 1) [NCBI Gene 3098] {aka CNSHA5, HK, HK1-ta, HK1-tb, HK1-tc, HKD}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, Slc27a1 (solute carrier family 27 (fatty acid transporter), member 1) [NCBI Gene 26457] {aka FATP1, Fatp, Vlc27a1}, Pnpla2 (patatin-like phospholipase domain containing 2) [NCBI Gene 66853] {aka 0610039C21Rik, 1110001C14Rik, Atgl, TTS-2.2}, Myc (Myc proto-oncogene, bHLH transcription factor) [NCBI Gene 17869] {aka Myc2, Niard, Nird, bHLHe39}, Fabp3 (fatty acid binding protein 3, muscle and heart) [NCBI Gene 14077] {aka Fabph-1, Fabph-4, Fabph1, Fabph4, H-FABP, Mdgi}, Erbb2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 13866] {aka Erbb-2, HER-2, HER2, Neu, c-erbB2, c-neu}
- **Diseases:** mammary tumors (MESH:D015674), hypoxic (MESH:D002534), hypoxia (MESH:D000860), prostate cancer (MESH:D011471), Cancer (MESH:D009369), TNBC (MESH:D064726), Breast cancer (MESH:D001943), metastasis (MESH:D009362), deaths (MESH:D003643), toxicity (MESH:D064420)
- **Chemicals:** water (MESH:D014867), free fatty acids (MESH:D005230), isoflurane (MESH:D007530), TMRE (MESH:C110932), FL (MESH:D005459), perphenazine (MESH:D010546), Bodipy (MESH:C095489), 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (MESH:C543305), fats (MESH:D005223), sugars (MESH:D000073893), oxygen (MESH:D010100), CCCP (MESH:D002258), streptomycin (MESH:D013307), Etomoxir (MESH:C054207), CO2 (MESH:D002245), glutamine (MESH:D005973), lipid (MESH:D008055), glucose (MESH:D005947), Bodipy FL C16low (-), 2-NBDG (MESH:C098340), palmitate (MESH:D010168), penicillin (MESH:D010406), amino acid (MESH:D000596), serine (MESH:D012694), Fatty acid (MESH:D005227)
- **Species:** Mycoplasma (genus) [taxon 2093], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** 4T1s — Mus musculus (Mouse), Hybridoma (CVCL_U609), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), CRL-2539 — Homo sapiens (Human), Turner syndrome, Transformed cell line (CVCL_9K25)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12964118/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12964118/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12964118/full.md

---
Source: https://tomesphere.com/paper/PMC12964118